Ravidasvir Explained

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.

It is on the World Health Organization's List of Essential Medicines.^[1]

Preliminary clinical trial results were announced in Nov 2015.^[2] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.^[3] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.^{[4] [5]}

Notes and References

1. Book: ((World Health Organization)) . The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) . 2023 . 10665/371090 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2023.02 . free .
2. Web site: Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4 . November 24, 2015 . Hepatitis Magazine .
3. Web site: Non-profit's $300 hepatitis C cure as effective as $84,000 alternative . Kollewe J . . 13 April 2018 .
4. Web site: List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.
5. Web site: 2021-06-14. First hepatitis C treatment developed through South-South cooperation registered in Malaysia DNDi. 2021-08-10. dndi.org. en-GB.